Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes
Baris D. Yildiz – 14 December 2018
Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?
Christian B. Ramers, Stacey B. Trooskin – 14 December 2018
Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
PRO: Patients With Hepatitis C Virus With Pretreatment Metavir Stage 3 Fibrosis Do Not Require Hepatocellular Carcinoma Surveillance After Sustained Virological Response
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Epidemiology of Hepatitis C
Syed‐Mohammed Jafri, Stuart C. Gordon – 14 December 2018
Hepatitis C Virus Standard of Care: A Rapid Evolution and Considerations for Acute Hepatitis C Virus
Tram T. Tran – 14 December 2018
MicroRNAs: Unfolding the Link Between Inositol‐Requiring Enzyme 1α and Fatty Liver
Xiaoying Liu, Richard M. Green – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.